KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Diluted Average) (2016 - 2025)

Arbutus Biopharma's Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $191.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 1.47% year-over-year to $191.8 million; the TTM value through Sep 2025 reached $191.8 million, up 1.47%, while the annual FY2024 figure was $185.6 million, 11.84% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $191.8 million at Arbutus Biopharma, roughly flat from $192.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $192.4 million in Q2 2025 and bottomed at $93.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $166.0 million (2023), against an average of $156.2 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) skyrocketed 58.86% in 2022 before it increased 1.47% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $106.2 million in 2021, then skyrocketed by 42.07% to $150.9 million in 2022, then rose by 9.95% to $166.0 million in 2023, then grew by 11.84% to $185.6 million in 2024, then rose by 3.32% to $191.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Shares Outstanding (Diluted Average) are $191.8 million (Q3 2025), $192.4 million (Q2 2025), and $190.7 million (Q1 2025).